69例耐多药肺结核个体化治疗的疗效分析

中国防痨杂志 ›› 2004, Vol. 26 ›› Issue (5): 257-260.

69例耐多药肺结核个体化治疗的疗效分析

黄学锐；高微微；卜建玲；戈启平；马玙；

北京市结核病与胸部肿瘤研究所北京 101149；

出版日期:2004-05-10 发布日期:2004-11-03

Analysis of therapeutic effect on the individualized regimens for 69 patients with multi-drug resistant pulmonary tuberculosis

Huang Xuerui,Gao Weiwei,Bu Jianling,et al.

Beijing Tuberculosis and Thoracic Tumor Institute,Beijing 101149

Online:2004-05-10 Published:2004-11-03

摘要/Abstract

摘要： 目的　观察与分析69例耐多药肺结核病人个体化综合治疗的疗效。方法根据耐药情况将病人分为3组,HR耐药组(Ⅰ组)、HR+1药耐药组(Ⅱ组)和≥HR+2药耐药组(Ⅲ组)制定个体化方案,观察痰菌阴转率及胸部X线好转率。结果 3组6、12及24月的痰菌阴转率及胸部X线好转率各为Ⅰ组:76.5%,94.1%,94.1%,94.1%;Ⅱ组:60.0%,65.0%,70.0%,80.0%;Ⅲ组:46.9%,50.0%,46.9%,56.3%。Ⅰ组、Ⅲ组疗效比较均有显著性差异(P<0.05,P<0.01,P<0.01)而与Ⅱ组比较无显著性差异。结论个体化方案治疗失败与耐多种药物、肺部不可逆性病变及病变广泛有关。根据药敏结果及早建立个体化的合理、有效的化疗方案对MDRTB是十分重要的。

关键词: 结核,肺/药物疗法, 结核,抗多种药物性, 个体化

Abstract: Objective To observe and analyse the therapeutic effects of individualized regimens for 69 patients with multi drug resistant pulmonary tuberculosis (MDR TB).Methods The patients were divided into 3 groups according to the result of susceptibility test.Three groups were HR resistant group (Group Ⅰ),resistant to 3 drugs including HR (Group Ⅱ) and resistant to 4 or more drugs including HR group (Group Ⅲ).And the patients received individualized regimens for treatment.Sputum negative conversion rates and chest X ray improvement rates were observed.Results The sputum conversion rates and chest X ray improvement rates of 3 groups in the treatment of 6,12 and 24 months:the sputum conversion rates and chest X ray improvement rates in Group Ⅰ were 76.5%,94.1%,94.1,94.1,Group Ⅱ were 60.0%,65.0%,70.0%,80.0% and Group Ⅲ were 46.9%,50.0%,46.9%,56.3% respectively.The rates of Group Ⅰ were higher significantly than that of Group Ⅲ ( P<0.05,P<0.01,P<0.01). There was no difference between Group Ⅰ and Ⅱ/Conclusion Individualized regimens therapeutic effects were associated with the number of resistant drugs and irreversible lesions.Our Results obtained in this study suggested that timely individualized regimens were provided to MDR TB patients based on the susceptibility test is improtant for the treatment.

Key words: Tuberculosis pulmonary/drug therapy, Tuberculosis,multidrug resistant, Individuation

黄学锐,高微微,卜建玲,戈启平,马玙,. 69例耐多药肺结核个体化治疗的疗效分析[J]. 中国防痨杂志, 2004, 26(5): 257-260.

Huang Xuerui,Gao Weiwei,Bu Jianling,et al.. Analysis of therapeutic effect on the individualized regimens for 69 patients with multi-drug resistant pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2004, 26(5): 257-260.

[1]	王琪. 精细化检后护理干预在体检发现肺小结节人群中的应用价值[J]. 中国防痨杂志, 2024, 46(S2): 434-436.
[2]	杨洪, 卢伟力, 张斌, 彭春仙. 个体化综合管理模式对结核病与糖尿病共病患者血糖控制和结核病治疗效果的作用[J]. 中国防痨杂志, 2024, 46(S1): 157-159.
[3]	赵嫄，雷倩，党丽云，等. 抗结核药物血药浓度监测工作的思考和展望[J]. 中国防痨杂志, 2017, 39(11): 1228-1232.
[4]	刘旭晖，卢水华. 精准医学与结核病临床诊治[J]. 中国防痨杂志, 2016, 38(3): 169-172.
[5]	姚晓伟，董昭良，李卓，高建国，姚黎明，刘丰胜，贾晨光. 60例耐药脊柱结核患者个体化治疗及疗效的临床研究[J]. 中国防痨杂志, 2016, 38(11): 978-984.